TILT is open to collaborations with pharmaceutical companies, specifically in the context of enhancing the therapeutic efficacy of cancer immunotherapies in development by stimulating T cells.

We are also looking to explore licensing agreements to support the commercialization of our pipeline.

Our current partners

The company’s approach has been validated through several partnerships, including ones with Merck-Pfizer-Alliance, with MSD and with Biotheus for TILT-123’s development in Greater China.

TILT has also collaborated with academic institutes such as University of Pennsylvania, exploring the use of TILT-123, combined with CAR-T, in solid tumors, as well as the Cancer Gene Therapy Group at the University of Helsinki.


If you are interested in discussing partnering opportunities with TILT then please contact: